Alto Neuroscience, Inc.

Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $24.32 and traded as high as $25.45. Alto Neuroscience shares last traded at $25.1850, with a volume of 616,285 shares changing hands. Analyst

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on November 3, 2026, the Compensation and Management Development Committee of Alto's Board of Directors granted a new employee an option to purchase 50,000 shares of Alto's common stock. The stock option was granted under Alto's 2025 Inducement P…

Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neurop

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Healthcare Conference, September 14-16, 2026 Format: Fireside chat and one-on-one meetings Presentation D…

Shares of Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report) have received a consensus rating of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eight have issued a buy recommendation on

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead Alto's finance function and oversee corporate strategy and business development, reporting to Amit Etkin, M.D., Ph.D., Alto's founder, chief executive…

AWM Investment Company Inc. bought a new position in shares of Alto Neuroscience, Inc. (NYSE: ANRO) during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 80,000 shares of the company's stock, valued at approximately $2,111,000. AWM Investment Company Inc. owned approximately 0.23% of

Alto Neuroscience, Inc. (NYSE: ANRO - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday. The company traded as high as $36.99 and last traded at $36.4220, with a volume of 867909 shares traded. The stock had previously closed at $34.28. Analyst Upgrades and Downgrades Several research firms recently

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “The second quarter further strengthened the case for ALTO-207 and our conviction in the opportunity ahead …